Tavilermide

DB12441InvestigationalSmall molecule

Tavilermide has been investigated for the treatment of Dry Eye Syndromes.

Chemical structure of Tavilermide
Formula / weight
C24H32N6O11 · 580.551 g/mol (avg)
Code names
MIM-D3

Resolves to

Compound
UNIINMG938VJ6TCAS263251-78-1ChEMBLCHEMBL3544981PubChem9808372
Structure
InChIKeyDVJXNXPFYJIACK-ULQDDVLXSA-NSMILESNCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O
Targets
P04629NTRK1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Tavilermide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In